Aflac’s second quarter results were met with a negative market reaction, as sales declined year-over-year despite meeting Wall Street’s expectations. Management attributed the drop in revenue largely to tough comparisons in Japan following last year’s launch of the Miraito cancer insurance product, as well as shifting consumer preferences. CEO Daniel Amos emphasized that, while sales in Japan were down this quarter, new offerings like Tsumitasu and Anshin Palette produced solid growth. In the U.S., sales growth was modest but supported by strength in group voluntary products and network dental and vision, with disciplined expense management helping to preserve margins.

Is now the time to buy AFL? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Aflac’s Q2 Earnings Call

• Ryan Krueger (KBW): asked about the sustainability of Aflac’s asset repositioning efforts. Bradley Dyslin, Global Chief Investment Officer, said there are more opportunities ahead due to the higher rate environment and that the team will continue to pursue these moves.

• Thomas Gallagher (Evercore): inquired about Aflac’s appetite for larger M&A deals. CEO Daniel Amos replied the company remains open to strategic opportunities but will be disciplined, favoring smaller deals that fit operationally and financially.

• Suneet Kamath (Jefferies): questioned sequential declines in Japanese medical sales despite new product launches. Koichiro Yoshizumi, Aflac Japan’s Head of Marketing, explained that strong initial sales post-launch drove a high Q1, and momentum is expected to continue through the year.

• Michael Ward (UBS): asked if inflation and higher rates in Japan affected policy lapse rates. CFO Max Broden said lapses have not materially increased and recent changes are mostly due to product launches rather than economic conditions.

• Wilma Jackson Burdis (Raymond James): sought detail on the capital freed by expanding Japanese reinsurance. Broden indicated that the impact depends on product mix and block age, with greater benefits expected from medical business but no simple rule of thumb.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be watching (1) how the new product launches in Japan, particularly Tsumitasu and Anshin Palette, impact sales momentum and cross-selling rates; (2) whether the U.S. group business can sustain growth and drive higher adoption of dental and vision products; and (3) the effectiveness of continued investment portfolio repositioning in supporting net investment income and capital efficiency. Persistent inflation and evolving reinsurance strategies will also be key areas of focus.

Aflac currently trades at $120.60, down from $126.66 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.